

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515  
<http://lobbyingdisclosure.house.gov>

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510  
<http://www.senate.gov/lobby>

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual <u>BAYER CORPORATION (consolidated report)</u>			
<b>2. Address</b> Address1 <u>701 Pennsylvania Ave., NW Suite 720</u> Address2 _____ City <u>WASHINGTON</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>			
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____			
<b>4a. Contact Name</b> <u>Mr. JONATHAN COLLUM</u>		<b>b. Telephone Number</b> <u>2027378900</u> <b>c. E-mail</b> <u>jonathan.collum@bayer.com</u>	
		<b>5. Senate ID#</b> <u>5632-12</u>	
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality <u>BAYER CORPORATION (consolidated report)</u>		<b>6. House ID#</b> <u>312570000</u>	

## TYPE OF REPORT

8. Year 2012 Q1 (1/1 - 3/31) ☐ Q2 (4/1 - 6/30) ☐ Q3 (7/1 - 9/30) ☒ Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity ☐

## INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

<p align="center"><b>12. Lobbying</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSE</b> relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>1,290,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
--	---

**Signature** Digitally Signed By: Bob Walker - Head of Public Policy Communications

**Date** 10/22/2012

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

H. R. 525 Veterinary Public Health Amendments Act. An act to amend the Public Health Service Act to enhance and increase the number of veterinarians trained in veterinary public health.  
S 518 Veterinary Loan Repayment Program In support for legislation.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

--

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

HR 5973 FY 2013 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act. General provisions of the bill related to animal drugs and biologics.  
HR 5855 FY 2013 Homeland Security Appropriations Bill. Support for National Biodefense and Agriculture Facility funding.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAR

16. Specific lobbying issues

HR 5250/S 2763 To suspend temporarily the rate of duty on dimethyl carbonate polymer with 1,6 hexanediol copolymer and 2-oxepanone; (Provisions related to the reduction of tariffs)

HR 5251/S 2765 To suspend temporarily the rate of duty on 1,6 hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs)

HR 5250/S 2767 To suspend temporarily the rate of duty on 1,6-Hexanediol-dimethyl carbonate copolymer; (Provisions related to the reduction of tariffs.)

HR 5253/S 2770/S 2778 To suspend temporarily the rate of duty on reaction product of 3,5-dimethyl-1,2-diazole with polymer of hexane-1,6-diyl diisocyanate in organic solvent; (provisions related to the reduction of tariffs.)

HR 5236/S 2772 To suspend temporarily the duty on Desmodur BL 1100/1; (Provisions related to the reduction of tariffs).

HR 5235/S 2773 To suspend temporarily the duty on on Bayhydur BL 5335; (Provisions related to the reduction of tariffs.)

HR 5233/S 2775 To suspend temporarily the duty on Desmodur VP LS 2078/2; (Provisions related to the reduction of tariffs.)

HR 5229/S 2779 To suspend temporarily the duty on 1,6-Diisocyanato-hexane homopolymer, polyethylene-polypropylene glycol mono-Bu ether blocked (Provision related to the reduction of tariffs.)

HR 5234/S 2781 To suspend temporarily the duty on Bayhydur XP 2547; (Provision related to the reduction of tariffs.)

HR 5246/S 2783 To extend the temporary suspension of duty on 2-Oxepanone polymer with 1,4-butanediol and 5-isocyanato-1-(isocyanatomethyl)-1,3,3-trimethylcyclohexane, 2-ethyl-1-hexanol-blocked; (Provisions related to the reduction of tariffs.)

HR 5247/S 2788 To extend and modify the temporary suspension of duty on Desmodur R-E; (Provisions related to the reduction of tariffs.)

HR 5230/S 2784 To extend the temporary suspension of duty on Desmodur E 14; (Provision related to the reduction of tariffs.)

HR 5248/S 2760 To extend and modify the temporary suspension of duty on Poly(toluene diisocyanate); (Provisions related to the reduction of tariffs.)

HR 5249/S 2762 To extend and modify the temporary suspension of duty on Desmodur RF-E; (Provisions related to the reduction of tariffs.)

HR 5231/S 2786 To extend and modify the temporary suspension of duty on Desmodur HL BA; (Provisions related to the reduction of tariffs.)

HR 5276/S 2758 To extend and modify the temporary reduction of duty on o-Acetylsalicylic acid (Aspirin); (Provision related to the reduction of tariffs.)

HR 5277/S 3028 To extend the temporary suspension of duty on D-Mannose; (Provisions related to the reduction of tariffs.)

HR 5278/S 3026 To extend the temporary suspension of duty on propoxur (2-(1-methylethoxy)phenol methylcarbamate); (Provisions related to the reduction of tariffs.)

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Juliane H.	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

S 136 Ban Poisonous Additives Act of 2011- A bill to ban the use of bisphenol A in food containers, and for other purposes. All Provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.

HR 432-Ban Poisons Additives Act of 2011-A bill to ban Bis- phenol-A from all Food contact uses. All provisions related to banning Bisphenol-A.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Julie	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

--

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

H.R.840 : Safe Exploration Coming from Underwater Reserves of Energy Act or the SECURE Act Expedites drilling for oil or natural gas, if already permitted by the Minerals Management Service before May 3, 2010. Eliminates need for review by the Bureau of Ocean Energy Management, Regulation and Enforcement; and the National Environmental Policy Act of 1969 or any other similar statutes such as the Federal Water Pollution Control Act or the Marine Mammal Protection Act of 1972.  
Provisions related to offshore drilling and exploration.

S 352- American Energy Independence and Security Act of 2011. A bill to allow leases and exploration of oil and gas from the coastal plain. All provisions related to increased supply of natural gas.

S.629 : A bill to improve hydropower, and for other purposes.  
All provisions related to the advancement of alternative energy

S.630 : A bill to promote marine and hydrokinetic renewable energy research and development, and for other purposes. All provisions related to advancement of alternative energy

S.631 : A bill to extend certain Federal benefits and income tax provisions to energy generated by hydropower resources. All provisions related to provision of incentives for alternative power.

S398: A bill to increase energy efficiency and other purposes. The bill would reduce regulatory burden on appliance manufacturers, create energy and water savings and reduce the environmental impacts of energy production. All provisions related to enhancing energy efficiency.

H.R.2962 : Roofing Efficiency Jobs Act of 2011-a bill to amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. All provisions related to incentives to retrofit or build cool roofs.

S.1575 : Energy-Efficient Cool Roof Jobs Act-a bill amend the Internal Revenue Code to classify any qualified energy-efficient cool roof replacement property as 20-year property for depreciation purposes. All provisions related to incentives in this bill

S.1737 Sensible Accounting to Value Energy Act of 2011 (SAVE Act) a bill to improve the accuracy of mortgage underwriting. All provisions related to the creation of energy efficiency retrofit and construction jobs, and for other purposes.

H.R.2599 : PACE Assessment Protection Act of 2011- a bill to prevent Fannie Mae, Freddie Mac, and other Federal residential and commercial mortgage lending regulators from adopting policies that go against State and local property clean energy laws.  
All provisions related to the bill.

S. 3591, the Commercial Building Modernization Act (CBMA) introduced by Senators Snowe, Bingaman, Feinstein and Cardin. All provisions pertaining to extending and enhancing the tax reduction at Section 179D of the Internal Revenue Code for energy efficient commercial and multifamily buildings.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Dakotah	Smith			<input type="checkbox"/>
Julie	Van Egmond			<input type="checkbox"/>
Ronald F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

S 847 Safe Chemicals Act of 2011-A bill to modernize and extend the Toxic Substance Control Act of 1976. All provisions related to safety standard, testing, rules, listing, manufacturing, distribution and product stewardship.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Julie	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

S 709 Secure Chemical Facilities Act-a bill to insure adequate security is employed at chemical plants. All provisions related to chemical risk management, tiered assessments, audits, standard setting and inspections.  
 HR 908: Full Implementation of the Chemical Facilities Anti-Terrorism Act(CFATS) All provisions of the bill related to the reauthorization of CFATS through 2017

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Julie	Van Egmond			<input type="checkbox"/>
Dakotah	Smith			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

--



**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

S3552: Discussions on EPA regarding reauthorization of the Pesticide Registration Improvement Act  
H.R.872 and S. 3605: Reducing Regulatory Burdens Act of 2011. Provisions related to NPDES permits.  
S. 3240: Agriculture Reform, Food, and Jobs Act of 2012. Provisions related to NPDES permits.

H.R. 965 Title: The Federal Food, Drug, Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases. title II. General provisions in the bill.  
S 1211 Companion bill to to HR 965  
S 1053 Title: Veterinary Services Investment Act. General support of the bill.  
Farm bill - Discussion draft of House Farm bill. Provisions related to NPDES, PRIA, Pollinators.  
ESA - Discussions on biological opinions and impact on agriculture, and need for streamlined consultation process with National Marine Fisheries, and Fish and Wildlife Service.  
Spray Drift - Discussions on proposed EPA guidance for pesticide label language on preventing spray drift.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean	Reimers			<input type="checkbox"/>
Donna	Stephens			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

--

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAR

16. Specific lobbying issues

S. 3292: Temporary Duty Suspension Process Act of 2012. Provisions related to tariffs  
House and Senate  
H.R.4459 and S. 2725: To suspend temporarily the duty on Thidiazuron.  
H.R.4460 and S. 3135 : To extend the suspension of duty on Fenamidone.  
H.R.4461 and S.2702 : To extend the suspension of duty on Spirodiclofen.  
H.R.4462 and S.3137 : To extend the suspension of duty on 2,4-dichloroaniline.  
H.R.4463 and S.2723: To suspend temporarily the duty on Thiacloprid.  
H.R.4464 and S. 2700: To extend the suspension of duty on Pyrimethanil.  
H.R.4465 : To suspend temporarily the duty on Pyrasulfotole.  
H.R.4466 and S.2704: To suspend temporarily the duty on Fosetyl-Al.  
H.R.4538 and S.3020 : To extend the temporary suspension of duty on Permethrin.  
H.R.4575 : To modify and extend the temporary reduction of duty on Isoxaflutole.  
H.R.4576 and S.3015 : To modify and extend the temporary reduction of duty on Clothianidin.  
H.R.4578 and S. 3016: To suspend temporarily the duty on Triadimefon.  
H.R.4657 : To suspend temporarily the duty on mixtures containing ?-cyfluthrin.  
H.R.4658 : To extend the temporary reduction of duty on Deltamethrin.  
H.R.4660 : To reduce temporarily the duty on Thiencarbazone-methyl.  
H.R.4661 and S.3017: To extend the temporary suspension of duty on Spiromesifen.  
H.R.4662 : To suspend temporarily the duty on Trifloxystrobin.  
H.R.4663 and S. 2703: To modify and extend the temporary reduction of duty on 2-Acetylbutyrolactone.  
H.R.4664 : To suspend temporarily the duty on 1,3-Cyclohexanedione.  
H.R.4665 and S. 3132: To suspend temporarily the duty on Flubendiamide.  
H.R.4666 and S.2722 : To suspend temporarily the duty on Spirotetramat.  
H.R.4667 : To extend the temporary suspension of duty on Isoxadifen-Ethyl.  
H.R.4668 and S. 3024: To extend the temporary suspension of duty on Cyfluthrin.  
H.R.4669 : To modify and extend the temporary reduction of duty on ?-cyfluthrin.  
H.R.4670 : To reduce temporarily the duty on mixtures containing Trifloxystrobin and Prothioconazole.  
H.R.4671 : To suspend temporarily the rate of duty on certain mixtures containing Trifloxystrobin.  
H.R.4672 and S.2726 : To reduce temporarily the duty on mixtures containing Spirotetramat.  
H.R.4673 : To suspend temporarily the duty on mixtures containing Trifloxystrobin and Propiconazole.  
H.R.4675 and S. 2678: To reduce temporarily the duty on 1H-[1,2,4]Triazole.  
H.R.4676 and S. 3161 : To suspend temporarily the duty on mixtures of Indaziflam.  
H.R.4677 and S. 3162: To suspend temporarily the duty on mixtures of Flubendiamide.  
H.R.4678 and S. 2681: To suspend temporarily the duty on mixtures containing Fluopyram.  
H.R.4679 and S. 2719: To suspend temporarily the duty on mixtures containing Fluopyram and Prothioconazole.  
H.R.4680 and S.2720: To suspend temporarily the duty on mixtures containing Fluopyram and Trifloxystrobin.  
H.R.4681 and S.2721 : To suspend temporarily the duty on mixtures containing Fluopyram and Pyrimethanil.  
H.R.4682 and S. 3133: To suspend temporarily the duty on Fenhexamid.  
H.R.4683 and S.3134: To suspend temporarily the duty on Fluopicolide.  
H.R.4684 and S 3130: To suspend temporarily the duty on Fluopyram.  
H.R.4685 and S. 3131 : To suspend temporarily the duty on Indaziflam.  
H.R.4686 and S. 3021 : To extend the temporary suspension of duty on 4-Chlorobenzaldehyde.  
H.R.4687 and S.2701 : To extend the temporary suspension of duty on Phenmedipham.  
H.R.4694 and S.3160 : To reduce temporarily the duty on product mixtures containing Spiromesifen.  
H.R.4696 : To suspend temporarily the duty on product mixtures containing Clothianidin.  
H.R.4698 : To extend the suspension of duty on product mixtures containing ethofumesate.  
H.R.4699 : To suspend temporarily the duty on cyprosulfamide.  
H.R.4735 and S.2355 : To extend and modify the temporary reduction of duty on ACM.  
H.R.4736 and S.2356: To reduce temporarily the duty on Glufosinate-Ammonium (GA).  
H.R.4737 and S.2354 : To extend and modify the temporary reduction of duty on Oxadiazon.  
H.R.4876 and S. 3136: To extend the temporary reduction of duty on Imidacloprid.  
H.R.4878 and S. 2587 : To suspend temporarily the duty on 1-Naphthyl, N-methylcarbamate.  
H.R.4879 and S.2386 : To reduce temporarily the duty on Penflufen.  
H.R.4883 and S. 2385 : To suspend temporarily the duty on IMIDACLOPRID.  
H.R.4914 and S. 2680: To suspend temporarily the duty on mixtures containing Fluopyram and Tebuconazole.  
H.R.5592 and S. 3023 : To suspend temporarily the duty on mixtures containing beta-cyfluthrin.  
H.R.5591 and S. 3025: To modify and extend the temporary reduction of duty on beta-cyfluthrin.  
H.R.4695 and S. 3008: To reduce temporarily the duty on product mixtures containing Clothianidin and Bacillus Firmus strain I-1582.  
H.R.4874 and S. 2382: To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxaflutole, and Cyprosulfamide.  
H.R.4659: To suspend temporarily the duty on N-(4-Fluorophenyl)-2-hydroxy-N-(1-methylethyl)acetamide.  
H.R.4877: To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its ?-Cyfluthrin isomer.  
H.R.5565 and S.2384: To reduce temporarily the duty on mixtures containing Imidacloprid and Cyfluthrin or its beta-Cyfluthrin isomer.

H.R.4875 and S. 2383: To modify and extend the temporary reduction of duty on mixtures of imidacloprid with application adjuvants.  
H.R.4873 and S.2381: To suspend temporarily the duty on mixtures containing Imidacloprid and Thiodicarb.  
H.R.4577: To extend and modify the temporary reduction of duty on mixtures containing Isoxaflutole and Cyprosulfamide.  
H.R.5257 and S.3009: To extend the temporary suspension of duty on product mixtures containing mesosulfuron-methyl.  
H.R.4537 and S. 3019: To suspend temporarily the duty on Methyl 2-[(4-methyl-5-oxo-3-propoxy-4,5-dihydro-[1,2,4]triazole-1-carbonyl)sulfamoyl]benzoate, sodium salt.  
H.R.4536 and S.3018: To extend the temporary suspension of duty on 2-Chlorobenzyl chloride.  
H.R.5258 and S.3022: To suspend temporarily the rate of duty on certain mixtures containing Fenoxaprop-p-ethyl, Pyrasulfotole, Bromoxynil octanoate, Bromoxynil heptanoate, and Mefenpyr-diethyl.  
H.R.4697: To reduce temporarily the duty on product mixtures containing Pyrasulfotole, Bromoxynil Octanoate, and Bromoxynil Heptanoate, including application adjuvants.  
H.R.4574: To modify and extend the temporary reduction of duty on AE 0172747 Ether.  
H.R.4579: To suspend temporarily the duty on mixtures containing Thiencarbazone-methyl, Isoxadifen-ethyl, and Tembotrione.  
H.R.4580: To suspend temporarily the duty on mixtures containing Trifloxystrobin, Clothianidin, Carboxin, and Metalaxyl.

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jean	Reimers			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BAN

16. Specific lobbying issues

HR 2779 Dodd-Frank Banking Regulations 2012 Amendments; (Provisions relating to OTC Derivatives "end user" waivers.)  
Policy on Comprehensive Tax Reform (no bill number); Provisions relating to tax reform legislation.)

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Ronald F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

HR 436 Healthcare Cost Reduction Act of 2012; (provisions related to medical device tax.)  
HR 4850 Enabling Energy Saving Innovations Act of 2012

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Ron F.	Docksai			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

H.R. 4223 the "Safe Doses Act"; H.R. 3668 the "Counterfeit Drug Penalty Enhancement Act of 2011"; and H.R. 4216 the "Foreign Counterfeit Prevention Act.", all parts,  
H.R. 2245, the Preserving Access to Life Saving Medications Act, Drug Shortage Issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11  
Combat Meth epidemic Act of 2005, sections pertaining to electronic reporting and stop sale  
Meth Lab Elimination Act of 2010, a draft by Sen. Wyden, all parts relating to pseudoephedrine

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas	Lilburn			<input type="checkbox"/>
Julie	Corcoran			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

S. 365, Balanced Budget control Act of 2011, sections pertaining to healthcare expenditures, Medicare Part D drug benefits

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas	Lilburn			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

### Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

### LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1			7		
2			8		
3			9		
4			10		
5			11		
6			12		

### ISSUE UPDATE

24. General lobbying issue that no longer pertains


**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address	City	State/Province	Zip	Country	
Bayer MaterialScience LLC	100 Bayer Rd. Pittsburgh		PA	15205	USA	City State Country
Bayer HealthCare LLC	6 West Belt Wayne		NJ	07470	USA	City State Country
Bayer CropScience LP	2 T.W. Alexander Dr. Research Triangle Park		NC	27709	USA	City State Country
Medrad Inc.	100 Global View Dr. Warrendale		PA	15086	USA	City State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

<b>1</b>	<b>4</b>	<b>7</b>
<b>2</b>	<b>5</b>	<b>8</b>
<b>3</b>	<b>6</b>	<b>9</b>

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	City	State/Province	Country		
				City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

<b>1</b>	<b>7</b>	<b>13</b>
<b>2</b>	<b>8</b>	<b>14</b>
<b>3</b>	<b>9</b>	<b>15</b>
<b>4</b>	<b>10</b>	<b>16</b>
<b>5</b>	<b>11</b>	<b>17</b>
<b>6</b>	<b>12</b>	<b>18</b>